NOVEL
  • Evie has broken new ground and is the first patented, approved slow release insemination device available for sale in the world. Reproductive Sciences (RSL) has an exclusivity agreement with its subsidiary in Israel, Fertiligent, to sell EVIE worldwide.
  • Research and trials show EVIE more than doubles the patients chances of success, compared with standard IUI, in the under 35 age group.
  • EVIE is less then half the cost per pregnancy (43%) when compared to IUI and a cost saving of over 40% when compared to IVF cost. 

 

Sources: (Combined analysis of EVIE data updated 13-3-17, Fertiligent data (<35 yrs only) and data supplied by the clinic Fertility Fusion, Wrightington, UK; average cost per pregnancy = midpoint of cost of treatment x average number of treatments expected to result in one pregnancy)

  • EVIE is convenient and the patient can leave the clinic shortly after the device has been fitted. EVIE can be removed by the patient after the four hour duration.
  • A clinical study in the US has shown EVIE is as comfortable as regular IUI for the patient.
  • In addition to targeting the IUI market, in time and with appropriate clinical data, EVIE will be able to capture a significant share of the IVF patient market segment.
  • Evie is fully developed and patented (US patent number 8088105) and US marketing approval (FDA 510(k)).

FIND YOUR LOCAL
CLINIC

Click Here

DOWNLOAD OUR MARKETING LITERATURE

PatientsClinicians

Image result for video camera icon

SEE OUR PRODUCT
VIDEO

Click Here